Nano-X Imaging Ltd. (NNOX) Stock Analysis and Metrics

Nano-X Imaging

NASDAQ: NNOX

$0.89 ▼ -0.08 (-8.47%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap67.53 Mn

P/E-0.85

P/S4.65

Div. Yield0.00

ROIC (Qtr)-0.26

Revenue Growth (1y) (Qtr)53.14

Add ratio to table…

About

NANO-X IMAGING LTD is a medical technology company that develops and commercializes an innovative digital X ray source and related imaging solutions.
Its core offering includes the Nanox. ARC hardware system the Nanox. CLOUD software platform the Nanox. AI artificial intelligence suite and the Nanox. MARKETPLACE teleradiology marketplace.
The company aims to make medical imaging more accessible and affordable by lowering the cost of hardware and integrating cloud based services AI analytics and remote radiology expertise.

Revenue is generated through the sale of Nanox. ARC systems under a capital expenditure model through subscription based medical software as a service fees for each scan performed and through licensing of its digital X ray technology to original equipment manufacturers.
Additional income comes from the sale of AI software solutions from its Nanox. AI business and from providing teleradiology services via the Nanox. MARKETPLACE platform.

NANO-X IMAGING LTD competes with established medical imaging manufacturers such as GE Healthcare Siemens Philips Canon Medical Systems and Hitachi while differentiating itself through its novel digital X ray source that eliminates the need for costly cooling components and enables a simpler system architecture.
Its integrated ecosystem combining hardware cloud AI analytics and a teleradiology network offers a unique end to end solution that can lower the total cost of ownership for hospitals clinics and urgent care providers.

The company serves hospitals clinics imaging centers urgent care facilities and health systems in the United States Europe Israel Africa and other regions.
Notable customers include Corewell which adopted Nanox. AI solutions Beilinson Hospital and Shamir Hospital in Israel which have participated in clinical trials of the Nanox. ARC system and the USARAD teleradiology network which provides remote radiology readings to approximately eighty customers across more than two hundred forty facilities.

Investment Thesis

▲ Bull case

Nanox is positioned to benefit from a structural shift in medical imaging adoption as its Nanox.ARC system gains traction through strategic distribution partnerships that convert pipeline commitments into revenue-generating deployments, with agreements like the Howard Technology Solutions deal targeting 300 systems over three years and cumulative commercial agreements totaling roughly 360 systems over two to three years, signaling a transition from technology provider to active deployment partner that aligns with the company’s stated goal of shifting toward a growing CapEx portion of revenue, which management explicitly identifies as the path to achieving its $35 million full-year 2026 revenue target, and the fact that approximately 38 systems are already at various stages of deployment—including demonstration, commercial installation, and pending regulatory approval—with an additional 15 expected to install in the near term as part of the Nanox Imaging Network, indicates that the ramp-up phase is underway and could accelerate as external bottlenecks like import licenses and construction timelines streamline with scale, creating a potential inflection point in the second half of 2026 as suggested by CFO Ran Daniel’s guidance that most of the revenue growth will materialize toward the latter part of the year once distribution agreements are fully operationalized.
The company’s strategic acquisition of VasoHealthcare IT, now operating as Nanox Health IT, provides an immediate and scalable revenue base with day-one contribution potential, as highlighted by the $0.4 million in revenue generated from this segment in Q4 FY25 alone following the November 19, 2025 acquisition, and the integration of this health IT platform enhances Nanox’s ability to embed its technology into clinical workflows, expand customer access, and support cross-ecosystem engagement between its AI, ARC, and teleradiology services, which management notes is already driving growth through new customer agreements and expansion of existing ones, while also serving as a lead-generation engine for USARAD Nanox.AI and Nanox.ARC deployments, thereby creating a synergistic flywheel where the Health IT business not only stabilizes near-term financials but also amplifies the commercial reach of the core imaging platform, reducing customer acquisition costs and increasing lifetime value per account.
Nanox is advancing regulatory and clinical validation milestones that could meaningfully expand its addressable market and reduce adoption barriers, including the TAP2D clearance in the U.S., which provides a practical 2D view output to enhance radiologist confidence in digital tomosynthesis images and addresses the adjunctive-use limitation that currently constrains broader utilization, the updated AMAR approval in Israel enabling use without adjunct limitation based on existing CE Mark, and the anticipated CE Mark submission for Europe in 2026, which, if approved, would unlock commercialization across key international markets, while clinical collaborations with institutions like Cedars-Sinai Medical Center—where the Nanox.AI aortic valve calcification solution demonstrated strong performance in retrospective analysis of 600 cases with six severe classifications identified and 100 clinically relevant findings—and the first U.S. institutional review board approval for a lung cancer screening trial with MDS Wellness in Michigan, underscore the growing evidence base supporting the system’s diagnostic equivalence and opportunistic screening value, which could accelerate reimbursement discussions and institutional adoption beyond niche use cases.
The restructuring of Nanox’s South Korean manufacturing operations, while involving a noncash impairment of $17.5 million in FY25, represents a strategic shift to a more efficient outsourced model with established partners like CSEM in Switzerland, which is expected to reduce structural and overhead costs, lower cash burn, and improve gross margin over time by aligning production with actual demand through a scalable, variable-cost supply chain, and the company’s plan to repurpose the Korean facility into an R&D center for ceramic tube development and next-generation emitter technology suggests that the move is not merely defensive but forward-looking, potentially lowering long-term unit costs and enabling innovation in high-margin OEM applications such as semiconductor inspection and security imaging, where recent progress includes a purchase order from a leading semiconductor equipment manufacturer for developmental emitters and ongoing evaluations by global imaging component suppliers, indicating that the technology platform has broader applicability beyond medical imaging that could diversify revenue streams and reduce reliance on the slower hospital procurement cycle.

Nanox is positioned to benefit from a structural shift in medical imaging adoption as its Nanox.ARC system gains traction through strategic distribution partnerships that convert pipeline commitments into revenue-generating deployments, with agreements like the Howard Technology Solutions deal targeting 300 systems over three years and cumulative commercial agreements totaling roughly 360 systems over two to three years, signaling a transition from technology provider to active deployment partner that aligns with the company’s stated goal of shifting toward a growing CapEx portion of revenue, which management explicitly identifies as the path to achieving its $35 million full-year 2026 revenue target, and the fact that approximately 38 systems are already at various stages of deployment—including demonstration, commercial installation, and pending regulatory approval—with an additional 15 expected to install in the near term as part of the Nanox Imaging Network, indicates that the ramp-up phase is underway and could accelerate as external bottlenecks like import licenses and construction timelines streamline with scale, creating a potential inflection point in the second half of 2026 as suggested by CFO Ran Daniel’s guidance that most of the revenue growth will materialize toward the latter part of the year once distribution agreements are fully operationalized.
The company’s strategic acquisition of VasoHealthcare IT, now operating as Nanox Health IT, provides an immediate and scalable revenue base with day-one contribution potential, as highlighted by the $0.4 million in revenue generated from this segment in Q4 FY25 alone following the November 19, 2025 acquisition, and the integration of this health IT platform enhances Nanox’s ability to embed its technology into clinical workflows, expand customer access, and support cross-ecosystem engagement between its AI, ARC, and teleradiology services, which management notes is already driving growth through new customer agreements and expansion of existing ones, while also serving as a lead-generation engine for USARAD Nanox.AI and Nanox.ARC deployments, thereby creating a synergistic flywheel where the Health IT business not only stabilizes near-term financials but also amplifies the commercial reach of the core imaging platform, reducing customer acquisition costs and increasing lifetime value per account.
Nanox is advancing regulatory and clinical validation milestones that could meaningfully expand its addressable market and reduce adoption barriers, including the TAP2D clearance in the U.S., which provides a practical 2D view output to enhance radiologist confidence in digital tomosynthesis images and addresses the adjunctive-use limitation that currently constrains broader utilization, the updated AMAR approval in Israel enabling use without adjunct limitation based on existing CE Mark, and the anticipated CE Mark submission for Europe in 2026, which, if approved, would unlock commercialization across key international markets, while clinical collaborations with institutions like Cedars-Sinai Medical Center—where the Nanox.AI aortic valve calcification solution demonstrated strong performance in retrospective analysis of 600 cases with six severe classifications identified and 100 clinically relevant findings—and the first U.S. institutional review board approval for a lung cancer screening trial with MDS Wellness in Michigan, underscore the growing evidence base supporting the system’s diagnostic equivalence and opportunistic screening value, which could accelerate reimbursement discussions and institutional adoption beyond niche use cases.
The restructuring of Nanox’s South Korean manufacturing operations, while involving a noncash impairment of $17.5 million in FY25, represents a strategic shift to a more efficient outsourced model with established partners like CSEM in Switzerland, which is expected to reduce structural and overhead costs, lower cash burn, and improve gross margin over time by aligning production with actual demand through a scalable, variable-cost supply chain, and the company’s plan to repurpose the Korean facility into an R&D center for ceramic tube development and next-generation emitter technology suggests that the move is not merely defensive but forward-looking, potentially lowering long-term unit costs and enabling innovation in high-margin OEM applications such as semiconductor inspection and security imaging, where recent progress includes a purchase order from a leading semiconductor equipment manufacturer for developmental emitters and ongoing evaluations by global imaging component suppliers, indicating that the technology platform has broader applicability beyond medical imaging that could diversify revenue streams and reduce reliance on the slower hospital procurement cycle.

▼ Bear case

Nanox’s path to meaningful revenue generation remains heavily dependent on the uncertain timing of system activation and transition to revenue-generating operations, as management explicitly acknowledges that a significant portion of the deployed base—estimated at 38 systems in various stages and 15 expected imminently—is not currently generating revenue, with ramp-up contingent on external factors such as import licenses, construction timelines, and regulatory approvals that are described as taking time to complete and subject to variability, and while the company targets $35 million in revenue for FY26, this implies a steep ramp from the $3.7 million reported in Q4 FY25, requiring nearly ninefold growth over three quarters, a trajectory that appears optimistic given the historical pace of deployment and the reliance on partners like Howard Industries to deliver on commitments, especially when the CFO concedes that most of the revenue growth will not materialize until the second half of 2026, leaving little room for error if any single partnership faces delays or if the onboarding process with nearly ten business partners proves more complex than anticipated due to coordination challenges and varying levels of partner readiness.
The company’s core teleradiology services, while showing incremental growth in Q4 FY25 with revenue increasing to $3.1 million from $2.8 million year-over-year, are unlikely to serve as a durable long-term growth engine, as management avoids providing specific guidance on this segment and the CFO’s noncommittal response—stating only that assumptions about low double-digit growth are “not far from real”—suggests a lack of confidence in its scalability, and given that this business currently represents the largest revenue driver, its modest growth trajectory raises concerns about the ability to fund operations and R&D without dilution or further cost-cutting, especially as the Nanox Health IT acquisition, while accretive, remains a relatively small contributor at $0.4 million in Q4 FY25 and may not scale rapidly enough to offset the inherent limitations of a teleradiology model that faces pricing pressure, competition from larger players, and limited differentiation beyond basic image reading services, which could cap its upside and leave the company overly reliant on the unproven commercial deployment of the Nanox.ARC system.
Regulatory progress, while noted as a priority, remains incomplete and uncertain, particularly regarding the removal of the adjunctive-use limitation in the U.S., which management identifies as a key priority to expand the addressable market but offers no timeline for, and the CE Mark submission for Europe, while anticipated in 2026, is explicitly stated to be subject to change based on regulatory priorities, introducing meaningful risk that approval could be delayed or require additional clinical data, and without these clearances, the Nanox.ARC system’s utility remains constrained to adjunctive use or specific niches like emergency departments and orthopedic practices, limiting its ability to displace traditional CT or X-ray in high-volume screening or diagnostic workflows, and while clinical validation studies with Cedars-Sinai and MDS Wellness are encouraging, they are still retrospective or early-stage, and the absence of large-scale, prospective outcomes data or reimbursement approvals means that the value proposition has not yet been proven at a scale sufficient to drive widespread hospital adoption or payer support, leaving the company vulnerable to slow uptake even if the technology performs well in controlled settings.
The ongoing cash burn and reliance on external financing pose a significant risk to near-term stability, as evidenced by the $33.4 million GAAP net loss in Q4 FY25—driven in part by the $17.5 million noncash impairment but also reflecting underlying operational losses—and while the company ended the quarter with approximately $60 million in cash, cash equivalents, and marketable securities, this buffer is thin given the quarterly cash outflow, and the recent sale of 4.2 million shares for $15.5 million in net proceeds indicates continued dependence on equity markets to fund operations, a situation that could be exacerbated if the anticipated second-half 2026 revenue ramp fails to materialize as expected, forcing further dilution or costly debt financing, and the restructuring plan, while intended to reduce overhead, is expected to incur additional cash-related expenses over its implementation period, with the CFO acknowledging that minor efficiency-related costs will likely be cash-based, meaning that the path to profitability remains distant and contingent on flawless execution across multiple uncertain variables, including partner performance, regulatory timelines, and clinical adoption rates, none of which are fully within the company’s control.

Nanox’s path to meaningful revenue generation remains heavily dependent on the uncertain timing of system activation and transition to revenue-generating operations, as management explicitly acknowledges that a significant portion of the deployed base—estimated at 38 systems in various stages and 15 expected imminently—is not currently generating revenue, with ramp-up contingent on external factors such as import licenses, construction timelines, and regulatory approvals that are described as taking time to complete and subject to variability, and while the company targets $35 million in revenue for FY26, this implies a steep ramp from the $3.7 million reported in Q4 FY25, requiring nearly ninefold growth over three quarters, a trajectory that appears optimistic given the historical pace of deployment and the reliance on partners like Howard Industries to deliver on commitments, especially when the CFO concedes that most of the revenue growth will not materialize until the second half of 2026, leaving little room for error if any single partnership faces delays or if the onboarding process with nearly ten business partners proves more complex than anticipated due to coordination challenges and varying levels of partner readiness.
The company’s core teleradiology services, while showing incremental growth in Q4 FY25 with revenue increasing to $3.1 million from $2.8 million year-over-year, are unlikely to serve as a durable long-term growth engine, as management avoids providing specific guidance on this segment and the CFO’s noncommittal response—stating only that assumptions about low double-digit growth are “not far from real”—suggests a lack of confidence in its scalability, and given that this business currently represents the largest revenue driver, its modest growth trajectory raises concerns about the ability to fund operations and R&D without dilution or further cost-cutting, especially as the Nanox Health IT acquisition, while accretive, remains a relatively small contributor at $0.4 million in Q4 FY25 and may not scale rapidly enough to offset the inherent limitations of a teleradiology model that faces pricing pressure, competition from larger players, and limited differentiation beyond basic image reading services, which could cap its upside and leave the company overly reliant on the unproven commercial deployment of the Nanox.ARC system.
Regulatory progress, while noted as a priority, remains incomplete and uncertain, particularly regarding the removal of the adjunctive-use limitation in the U.S., which management identifies as a key priority to expand the addressable market but offers no timeline for, and the CE Mark submission for Europe, while anticipated in 2026, is explicitly stated to be subject to change based on regulatory priorities, introducing meaningful risk that approval could be delayed or require additional clinical data, and without these clearances, the Nanox.ARC system’s utility remains constrained to adjunctive use or specific niches like emergency departments and orthopedic practices, limiting its ability to displace traditional CT or X-ray in high-volume screening or diagnostic workflows, and while clinical validation studies with Cedars-Sinai and MDS Wellness are encouraging, they are still retrospective or early-stage, and the absence of large-scale, prospective outcomes data or reimbursement approvals means that the value proposition has not yet been proven at a scale sufficient to drive widespread hospital adoption or payer support, leaving the company vulnerable to slow uptake even if the technology performs well in controlled settings.
The ongoing cash burn and reliance on external financing pose a significant risk to near-term stability, as evidenced by the $33.4 million GAAP net loss in Q4 FY25—driven in part by the $17.5 million noncash impairment but also reflecting underlying operational losses—and while the company ended the quarter with approximately $60 million in cash, cash equivalents, and marketable securities, this buffer is thin given the quarterly cash outflow, and the recent sale of 4.2 million shares for $15.5 million in net proceeds indicates continued dependence on equity markets to fund operations, a situation that could be exacerbated if the anticipated second-half 2026 revenue ramp fails to materialize as expected, forcing further dilution or costly debt financing, and the restructuring plan, while intended to reduce overhead, is expected to incur additional cash-related expenses over its implementation period, with the CFO acknowledging that minor efficiency-related costs will likely be cash-based, meaning that the path to profitability remains distant and contingent on flawless execution across multiple uncertain variables, including partner performance, regulatory timelines, and clinical adoption rates, none of which are fully within the company’s control.

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password